Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center.

ABSTRACT:

Objectives

Metformin is the only oral therapy for youth with type 2 diabetes, but up to 50% require additional agents within 2 years of diagnosis. Extended-release (XR) metformin formulations may improve adherence and tolerability-important mediators of treatment response-but data in youth is lacking. To evaluate rates of gastrointestinal (GI) symptoms in patients treated with metformin (SR and XR) and the change in GI symptoms after changes in metformin therapy.

Research design and methods

Retrospective chart review of youth with Type 2 or prediabetes seen in a multidisciplinary clinic during 2016-2019.

Results

Of 488 eligible patients, 41.4% and 21.1% were taking metformin SR and XR respectively, with most (58%, n = 178/305) taking a total daily dose of ≥1500 mg/day

SUBMITTER: Meyers AG 

PROVIDER: S-EPMC10226371 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature